$4.91
+6.28%Price chart
Apr 17Apr 22Apr 27Apr 30May 5May 8May 13May 18
Key dataMay 18, 2026
Open$5.32
From 52W high−72.72%
Volume441020.00
Market cap$3.55M
P/E (TTM)—
P/S (TTM)70.7x
Div yield—
Key dataMay 18, 2026
Open
$5.32
From 52W high
−72.72%
Volume
441020.00
Market cap
$3.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
45.2
MomentumView details →
1D Return
+6.28%
YTD Return
−34.55%
SummaryUpdated Jun 1, 2026
Predictive Oncology Inc. (NASDAQ:POAI) is a knowledge-driven biotechnology company founded in 2002 and headquartered in Eagan, Minnesota. Originally incorporated as Precision Therapeutics Inc., the company rebranded to its current name in June 2019 to better reflect its focus on artificial intelligence-driven cancer research. The company has evolved from a traditional medical device manufacturer into a science-driven organization that leverages artificial intelligence and machine learning to advance personalized cancer therapies and drug discovery processes.
Similar companies
Latest newsMore news →
Axe Compute Inc. said directors and Chairman Charles L. Nuzum, Daniel E. Handley and Gregory S. St. Clair resigned effective October 27, 2026, and Christopher Miglino will become Chair of the Board on November 1, 2026.2d agoAxe Compute Inc. signed Penguin Solutions, Inc. as a strategic partner to accelerate delivery of its next-generation AI infrastructure.21d agoDuos Technologies sold its GPU-as-a-Service entity to Axe Compute, removing approximately $98.1 million of prospective equipment financing as Duos shifts to a pure-play AI colocation platform.30d ago